Sygnature appoints Dr David Lustig to spearhead US expansion
Sygnature Discovery has appointed Dr David Lustig to the role of Vice President Business Development – United States. Dr Lustig will play a crucial role in the company’s US expansion, following the opening of our second US office at Oyster Point, South San Francisco in April.
A significant part of Sygnature’s customer base is already located in North America, ranging from major pharma through to small seed-funded biotechs, based all across the US and over the border in Canada. Facing growing demand from the US market over recent years, our appointment of Dr Lustig and the recent opening of a west coast office aim to establish a stronger presence that can better service both existing and future customers.
Dr Lustig received a Ph.D. in chemistry from the University of Michigan, and has over 25 years of experience in the pharmaceutical industry at Syntex, Roche, CV Therapeutics, Optivia Biotechnology and Aptuit, spanning scientific, business development, licensing, commercialisation and executive roles. David founded and led 2 companies and has a successful track record of bringing projects from concept to the market at 3 start-ups.
“I’m very excited about the future with Sygnature, and there is so much growth potential for us in the US market,” said Dr Lustig. “I have been a customer of drug discovery services myself, and I can say there are few companies out there with such a comprehensive integrated offering, that can take a project all the way from target to IND candidate, headed by teams of truly accomplished drug hunters.
“Many organisations still piecemeal out the different stages of the drug discovery journey to CROs across the world, but partnering with Sygnature means that our experienced scientists become part of the project’s discovery team, solving problems, pushing things forward, and more importantly coming up with a candidate that will have legs in the clinic. That’s an easy product to get behind. Now, my mission is to make sure that companies in the US are served with the breadth and quality of our incredible offering.”
Dr Paul Overton, Chief Commercial Officer at Sygnature, added: “David has been on both sides of the table, delivering drug discovery services himself, as well as outsourcing integrated projects to CROs. His passion for integrated drug discovery and his deep knowledge of the pharmaceutical R&D space make him the ideal candidate to develop relationships with companies in the US, advising potential customers on the value creation of working with a truly integrated discovery partner.”